Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series
By
Giulia Odorici
Cinzia Buligan
Carolina Fantini
Lucia Mantovani
Giulia Rech
Lidia Sacchelli
July 14, 2026
Clinical Scorecard: Clinical Insights on Tildrakizumab 200 mg for Managing Complex Psoriasis: A Case Series Analysis
At a Glance
Category Detail
Condition Moderate-to-severe plaque psoriasis Key Mechanisms Inhibition of IL-23p19 interaction with its receptor Target Population Patients with high disease burden and multiple comorbidities Care Setting Real-world clinical practice
Key Highlights
Tildrakizumab 200 mg induced complete remissions (PASI100) in four out of six patients. Most patients achieved PASI90 or PASI100 responses within 4–12 weeks. Treatment effectiveness was maintained over approximately 24 months. Guideline-Based Recommendations
Diagnosis
Consider the presence of comorbidities and disease burden in diagnosis. Management
Utilize tildrakizumab 200 mg for patients with high disease burden and prior treatment failures. Monitoring & Follow-up
Monitor treatment responses and comorbidities over time. Risks
Assess risks associated with comorbidities when prescribing biologics. Patient & Prescribing Data
Patients with moderate-to-severe psoriasis and multiple comorbidities.
Remove unsupported claims.
Clinical Best Practices
Evaluate comorbidities when selecting treatment options. Related Resources & Content
